Neumora's Depression Drug Fails Phase 3 Trials; enGene to Cut Staff by Half
Shares of Neumora Therapeutics dropped significantly after its depression drug, navacaprant, failed two Phase 3 trials. The company announced it will discontinue development for the drug and shift focus to other therapeutic areas such as obesity, schizophrenia, and Alzheimer’s disease agitation. Meanwhile, enGene plans to lay off half of its workforce and halt enrollment in parts of a gene therapy trial due to financial constraints.
